Active Ingredient History
Nintedanib is a receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. It is the only kinase inhibitor drug approved to treat idiopathic pulmonary fibrosis. that targets multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, and Fms-like tyrosine kinase-3 (FLT3). Among them, FGFR, PDGFR, and VEGFR have been implicated in IPF pathogenesis. Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these receptors and blocks the intracellular signaling which is crucial for the proliferation, migration, and transformation of fibroblasts representing essential mechanisms of the IPF pathology. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma of Lung (Phase 1/Phase 2)
Appendiceal Neoplasms (Phase 2)
Asbestosis (Phase 2)
Astrocytoma (Phase 2)
Breast Neoplasms (Phase 2)
Bronchiolitis (Phase 2)
Carcinoid Tumor (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Colonic Neoplasms (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
COVID-19 (Phase 4)
Drug Interactions (Phase 1)
Drugs, Investigational (Phase 2)
Endometrial Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Fibroblasts (Phase 1)
Genital Neoplasms, Female (Phase 1)
Glioblastoma (Phase 2)
Gliosarcoma (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Hepatic Insufficiency (Phase 1)
Leukemia, Myeloid, Acute (Phase 1/Phase 2)
Lung Diseases (Phase 4)
Lung Diseases, Interstitial (Phase 4)
Lung Neoplasms (Phase 2)
Lung Transplantation (Phase 3)
Lymphangioleiomyomatosis (Phase 2)
Melanoma (Phase 1/Phase 2)
Mesothelioma (Phase 3)
Mesothelioma, Malignant (Phase 2)
Multiple Myeloma (Phase 1)
Mutation (Phase 1/Phase 2)
Myopia (Phase 3)
Neoplasm Metastasis (Phase 2)
Neoplasms ()
Oligodendroglioma (Phase 2)
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 1/Phase 2)
Peritoneal Neoplasms (Phase 3)
Pharmacokinetics (Phase 2)
Platinum Compounds (Phase 2)
Pneumococcal Infections (Phase 2)
Prostatic Neoplasms (Phase 2)
Pterygium (Phase 3)
Pulmonary Fibrosis (Phase 4)
Radiation Pneumonitis (Phase 2)
Safety (Phase 2)
Sarcoma (Phase 2)
Scleroderma, Systemic (Phase 3)
Silicosis (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Telangiectasia, Hereditary Hemorrhagic (Phase 2)
Thyroid Neoplasms (Phase 2)
Tissue Adhesions (Phase 2/Phase 3)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
Volunteers (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
